



# InertSearch™ for LC

Inertsil® Applications

## Analysis of Valsartan and Hydrochlorothiazide

(Under the Condition of the draft for the Japanese Pharmacopoeia,  
Valsartan and Hydrochlorothiazide Tablets)

Data No. LB519-0812



### Conditions

**System** : GL7700 HPLC system  
**Column** : InertSustainSwift C18  
(5  $\mu$ m, 125 x 3.0 mm I.D.)  
**Column Cat. No.** : 5020-88250  
**Eluent** : A) CH<sub>3</sub>CN  
B) Buffer\*  
A/B = 20/80, v/v  
**Flow rate** : 0.9 mL/min  
**Col. Temp.** : 25 °C  
**Detection** : UV 225 nm (UV7750 UV Detector)  
**Injection Vol.** : 10  $\mu$ L  
**Sample** : Standard

\*Dissolve 14.68 g of Na<sub>2</sub>HPO<sub>4</sub> · 12H<sub>2</sub>O and  
3.81 g of KH<sub>2</sub>PO<sub>4</sub> in 1000 mL of water.

### Analyte:

1. Hydrochlorothiazide	7 mg/L
2. Valsartan	30 mg/L
Theoretical plates (2)	: 1,135 ( $\geq$ 500)
Symmetry factor (2)	: (0.7 $\leq$ ) 1.04 ( $\leq$ 1.5)
RSD of the peak area of 2 (%) (n=6)	: 0.06 ( $\leq$ 1.0)
Theoretical plates (1)	: 4,355 ( $\geq$ 3,000)
Symmetry factor (1)	: 1.17 ( $\leq$ 2.0)
RSD of the peak area of 1 (%) (n=6)	: 0.13 ( $\leq$ 1.0)